Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853020 · ClinicalTrials.gov registry record · Early Phase 1
Cannabinoids and Cerebellar-Motor Functioning
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 57
- Enrollment target
NCT01853020: Completed Early Phase 1 study, sponsored by Yale University.
NCT01853020 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 57 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01853020, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the dose-related effects of delta-9-tetrahydrocannabinol (∆9-THC) in healthy individuals on cerebellum-dependent motor functions.
Primary Outcome
% conditioned responses (CRs) will be measured
Interventions
- DRUG Placebo
- DRUG THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2012-12 |
| Est. Completion | 2015-04-07 |
| Phase | Early Phase 1 |
What the finished NCT01853020 record still lists
NCT01853020 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01853020 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01853020 about?
NCT01853020 is a clinical study titled "Cannabinoids and Cerebellar-Motor Functioning". The purpose of this study is to characterize the dose-related effects of delta-9-tetrahydrocannabinol (∆9-THC) in healthy individuals on cerebellum-dependent motor functions.
What is the current status of trial NCT01853020?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 57 participants. The study started on 2012-12. Estimated completion is 2015-04-07.
What interventions are being tested in trial NCT01853020?
The interventions under investigation include: Placebo (DRUG), THC (DRUG).
Who is sponsoring clinical trial NCT01853020?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01853020's enrollment target sits among peer trials
57 446th of 2000 higher than 1,551 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia